Syncom Formulations Q1 FY27 Standalone Revenue ₹124.66 Cr, Profit ₹24.59 Cr
Syncom Formulations reported Q1 FY27 standalone revenue of ₹124.66 crore and profit after tax of ₹24.59 crore. Consolidated revenue was ₹133.36 crore, with profit after tax at ₹24.85 crore. The results were approved by the Board on August 11, 2026.
The financial results are a key indicator for investors and can influence stock price. The reported figures show a positive trend.
The company reported increased revenue and profit for the quarter compared to the previous year, indicating positive financial performance.
Syncom Formulations (India) Limited has announced its un-audited standalone and consolidated financial results for the quarter ended June 30, 2026. The company's revenue from operations for the standalone entity stood at ₹124.66 crore, with other income amounting to ₹7.82 crore, leading to a total income of ₹132.48 crore.
Expenses for the quarter were ₹100.57 crore, resulting in a profit before exceptional items and tax of ₹31.91 crore. After considering tax expenses of ₹7.32 crore, the net profit for the period from continuing operations was ₹24.59 crore. The total comprehensive income for the period was ₹28.41 crore.
On a consolidated basis, the total income for the quarter was ₹133.36 crore, with expenses at ₹101.10 crore. This resulted in a profit before exceptional items and tax of ₹32.25 crore. After tax expenses of ₹7.40 crore, the consolidated profit for the period from continuing operations was ₹24.85 crore. The total comprehensive income on a consolidated basis stood at ₹28.67 crore.
The Board of Directors approved these results on August 11, 2026, following their review by the Audit Committee. The meeting commenced at 4:00 PM and concluded at 4:45 PM. The financial results will be published in English and Marathi newspapers and will also be hosted on the company's website in XBRL format.
What to do with a filing like this
Syncom Formulations (India) Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Syncom Formulations (India) Limited. Read the original for the full detail.